FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938506687> ?p ?o ?g. }

• W2938506687 abstract "BACKGROUND Secukinumab is administered at the labelled dose of 300 mg at weeks 0, 1, 2, 3, 4 (loading dose) and every 4 weeks thereafter. OBJECTIVES To investigate the efficacy of secukinumab administered without the initial loading dose in patients with psoriasis. METHODS This was a retrospective observational study including adult patients with psoriasis (n = 156) treated with secukinumab 300 mg administered either according to the labelled dose (n = 75) or without the initial loading dose (n = 81). Efficacy was evaluated by comparing the Psoriasis Area and Severity Index (PASI) 75 and PASI 90 response rates at week 8, 12, 16, 32 and 48. RESULTS For patients who received the labelled dose vs. those who did not, PASI 75 response rates were achieved at week 8, 12, 16, 32 and 48 by 60% vs. 40% (P < 0·01), 72% vs. 61% (P < 0·01), 77% vs. 75%, 85% vs. 77% and 79% vs. 78%, respectively. PASI 90 responses were achieved at the same time points by 45% vs. 31% (P < 0·01), 49% vs. 40% (P < 0·01), 54% vs. 47%, 55% vs. 47% and 57% vs. 54% for those who received the labelled dose vs. those who did not, respectively. A greater proportion of patients receiving secukinumab without the loading dose discontinued treatment because of inefficacy (25% vs. 13%, P < 0·05), particularly those with body weight greater than 80 kg. CONCLUSIONS Secukinumab administered without the loading dose is associated with a higher proportion of primary inefficacy, and achieved inferior results compared with the labelled dose at week 8 and week 12, but showed similar efficacy thereafter. What's already known about this topic? Secukinumab is an interleukin (IL)-17A inhibitor for chronic plaque psoriasis administered by subcutaneous injections at the labelled dose of 300 mg at weeks 0, 1, 2, 3, 4 (loading dose) and every 4 weeks thereafter (maintenance dose). Dose adjustment is common in clinical practice, and can consist of dose reduction when a prolonged remission is obtained or a dose increase in order to improve efficacy. What does this study add? The efficacy of secukinumab administered without the initial weekly loading dose was significantly inferior compared with the labelled dose in the short term, but was similar after week 16 and up to week 48. A greater proportion of patients receiving secukinumab without the loading dose showed primary inefficacy, particularly those with body weight greater than 80 kg." @default.
• W2938506687 created "2019-04-25" @default.
• W2938506687 creator A5016818733 @default.
• W2938506687 creator A5026709571 @default.
• W2938506687 creator A5078933224 @default.
• W2938506687 creator A5087192032 @default.
• W2938506687 date "2019-05-29" @default.
• W2938506687 modified "2023-09-24" @default.
• W2938506687 title "Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis" @default.
• W2938506687 cites W1611276153 @default.
• W2938506687 cites W1957267795 @default.
• W2938506687 cites W1973354423 @default.
• W2938506687 cites W2005176759 @default.
• W2938506687 cites W2319284972 @default.
• W2938506687 cites W2418506270 @default.
• W2938506687 cites W2540386754 @default.
• W2938506687 cites W2576647440 @default.
• W2938506687 cites W2593291425 @default.
• W2938506687 cites W2756224147 @default.
• W2938506687 cites W2756813587 @default.
• W2938506687 cites W2804124903 @default.
• W2938506687 cites W2891289063 @default.
• W2938506687 cites W2893165757 @default.
• W2938506687 doi "https://doi.org/10.1111/bjd.18015" @default.
• W2938506687 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31004509" @default.
• W2938506687 hasPublicationYear "2019" @default.
• W2938506687 type Work @default.
• W2938506687 sameAs 2938506687 @default.
• W2938506687 citedByCount "3" @default.
• W2938506687 countsByYear W29385066872019 @default.
• W2938506687 countsByYear W29385066872022 @default.
• W2938506687 crossrefType "journal-article" @default.
• W2938506687 hasAuthorship W2938506687A5016818733 @default.
• W2938506687 hasAuthorship W2938506687A5026709571 @default.
• W2938506687 hasAuthorship W2938506687A5078933224 @default.
• W2938506687 hasAuthorship W2938506687A5087192032 @default.
• W2938506687 hasConcept C16005928 @default.
• W2938506687 hasConcept C2776260265 @default.
• W2938506687 hasConcept C2779786854 @default.
• W2938506687 hasConcept C2780564577 @default.
• W2938506687 hasConcept C3020604521 @default.
• W2938506687 hasConcept C71924100 @default.
• W2938506687 hasConceptScore W2938506687C16005928 @default.
• W2938506687 hasConceptScore W2938506687C2776260265 @default.
• W2938506687 hasConceptScore W2938506687C2779786854 @default.
• W2938506687 hasConceptScore W2938506687C2780564577 @default.
• W2938506687 hasConceptScore W2938506687C3020604521 @default.
• W2938506687 hasConceptScore W2938506687C71924100 @default.
• W2938506687 hasLocation W29385066871 @default.
• W2938506687 hasOpenAccess W2938506687 @default.
• W2938506687 hasPrimaryLocation W29385066871 @default.
• W2938506687 hasRelatedWork W2893977181 @default.
• W2938506687 hasRelatedWork W2895404113 @default.
• W2938506687 hasRelatedWork W2904527393 @default.
• W2938506687 hasRelatedWork W2920791236 @default.
• W2938506687 hasRelatedWork W2975758879 @default.
• W2938506687 hasRelatedWork W3004606541 @default.
• W2938506687 hasRelatedWork W3013560340 @default.
• W2938506687 hasRelatedWork W3173895359 @default.
• W2938506687 hasRelatedWork W4234288250 @default.
• W2938506687 hasRelatedWork W4248245481 @default.
• W2938506687 isParatext "false" @default.
• W2938506687 isRetracted "false" @default.
• W2938506687 magId "2938506687" @default.
• W2938506687 workType "article" @default.